Advancements in cellular immunotherapy: overcoming resistance in lung and colorectal cancer

Immunotherapy has revolutionized cancer treatment, offering hope for patients with otherwise treatment-resistant tumors. Among the most promising approaches are cellular therapies, particularly chimeric antigen receptor T-cell (CAR-T) therapy, which has shown remarkable success in hematologic malign...

Full description

Saved in:
Bibliographic Details
Main Authors: Lijuan Qin, Yuan Li, Juan Liu, Xiaoqin An
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1554256/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832539893086027776
author Lijuan Qin
Yuan Li
Juan Liu
Xiaoqin An
author_facet Lijuan Qin
Yuan Li
Juan Liu
Xiaoqin An
author_sort Lijuan Qin
collection DOAJ
description Immunotherapy has revolutionized cancer treatment, offering hope for patients with otherwise treatment-resistant tumors. Among the most promising approaches are cellular therapies, particularly chimeric antigen receptor T-cell (CAR-T) therapy, which has shown remarkable success in hematologic malignancies. However, the application of these therapies to solid tumors, such as lung and colorectal cancers, has faced significant challenges. Tumor resistance mechanisms—ranging from immune evasion, antigen loss, and immune checkpoint upregulation, to tumor microenvironment immunosuppression—remain major obstacles. This mini-review highlights the latest advancements in tumor immunotherapy, with a focus on cellular therapies, and addresses the resistance mechanisms that hinder their effectiveness in lung and colorectal cancers. We examine the evolution of CAR-T cell therapy, as well as the potential of engineered natural killer (NK) cells and macrophages in solid tumor treatment. The review also explores cutting-edge strategies aimed at overcoming resistance, including combination therapies, gene editing technologies, and nanotechnology for targeted drug delivery. By discussing the molecular, cellular, and microenvironmental factors contributing to resistance, we aim to provide a comprehensive overview of how these challenges can be overcome, paving the way for more effective, personalized immunotherapies in lung and colorectal cancer treatment.
format Article
id doaj-art-5431b7a732294e9781acc1d456d7dc36
institution Kabale University
issn 1664-3224
language English
publishDate 2025-02-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj-art-5431b7a732294e9781acc1d456d7dc362025-02-05T07:32:45ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-02-011610.3389/fimmu.2025.15542561554256Advancements in cellular immunotherapy: overcoming resistance in lung and colorectal cancerLijuan Qin0Yuan Li1Juan Liu2Xiaoqin An3Department of Radiotherapy, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, ChinaDepartment of Respiratory Medicine, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, ChinaDepartment of Special needs Medicine, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, ChinaDepartment of Respiratory Medicine, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, ChinaImmunotherapy has revolutionized cancer treatment, offering hope for patients with otherwise treatment-resistant tumors. Among the most promising approaches are cellular therapies, particularly chimeric antigen receptor T-cell (CAR-T) therapy, which has shown remarkable success in hematologic malignancies. However, the application of these therapies to solid tumors, such as lung and colorectal cancers, has faced significant challenges. Tumor resistance mechanisms—ranging from immune evasion, antigen loss, and immune checkpoint upregulation, to tumor microenvironment immunosuppression—remain major obstacles. This mini-review highlights the latest advancements in tumor immunotherapy, with a focus on cellular therapies, and addresses the resistance mechanisms that hinder their effectiveness in lung and colorectal cancers. We examine the evolution of CAR-T cell therapy, as well as the potential of engineered natural killer (NK) cells and macrophages in solid tumor treatment. The review also explores cutting-edge strategies aimed at overcoming resistance, including combination therapies, gene editing technologies, and nanotechnology for targeted drug delivery. By discussing the molecular, cellular, and microenvironmental factors contributing to resistance, we aim to provide a comprehensive overview of how these challenges can be overcome, paving the way for more effective, personalized immunotherapies in lung and colorectal cancer treatment.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1554256/fullimmunotherapyCAR-T cellslung cancercolorectal cancerresistance mechanisms
spellingShingle Lijuan Qin
Yuan Li
Juan Liu
Xiaoqin An
Advancements in cellular immunotherapy: overcoming resistance in lung and colorectal cancer
Frontiers in Immunology
immunotherapy
CAR-T cells
lung cancer
colorectal cancer
resistance mechanisms
title Advancements in cellular immunotherapy: overcoming resistance in lung and colorectal cancer
title_full Advancements in cellular immunotherapy: overcoming resistance in lung and colorectal cancer
title_fullStr Advancements in cellular immunotherapy: overcoming resistance in lung and colorectal cancer
title_full_unstemmed Advancements in cellular immunotherapy: overcoming resistance in lung and colorectal cancer
title_short Advancements in cellular immunotherapy: overcoming resistance in lung and colorectal cancer
title_sort advancements in cellular immunotherapy overcoming resistance in lung and colorectal cancer
topic immunotherapy
CAR-T cells
lung cancer
colorectal cancer
resistance mechanisms
url https://www.frontiersin.org/articles/10.3389/fimmu.2025.1554256/full
work_keys_str_mv AT lijuanqin advancementsincellularimmunotherapyovercomingresistanceinlungandcolorectalcancer
AT yuanli advancementsincellularimmunotherapyovercomingresistanceinlungandcolorectalcancer
AT juanliu advancementsincellularimmunotherapyovercomingresistanceinlungandcolorectalcancer
AT xiaoqinan advancementsincellularimmunotherapyovercomingresistanceinlungandcolorectalcancer